AusCann up more than 65pc after completing testing of hard-shell capsules, page-84

Back to the real topics:
Earlier this month, stockbrokers Morgan’s summed up the state of play, “We view the
medical cannabis industry as a crowded trade and difficult space to navigate in the current
regulatory environment. Low levels of differentiation, slow moving regulation, weak clinical
evidence of efficacy, and expensive treatment costs compared to [Pharmaceutical
Benefits Scheme]-covered medicine makes it a slower moving proposition compared to
traditional drug assets.”
Market response also slowed with the decline in perceived value of licences following a
rash of issuance: at October 31, 2019 the Federal Office of Drug Control had issued 18
medical cannabis licences, eight cannabis research licences, 21 manufacture licences,
and 22 importation licences.